Molecular predictors of response to pembrolizumab in thymic carcinoma

Thymic carcinoma is rare and has a poorer prognosis than thymomas. The treatment options are limited after failure of platinum-based chemotherapy. We previously performed a single-center phase II study of pembrolizumab in patients with advanced thymic carcinoma, showing a 22.5% response rate. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yongfeng, Ramesh, Archana, Gusev, Yuriy, Bhuvaneshwar, Krithika, Giaccone, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484507/
https://www.ncbi.nlm.nih.gov/pubmed/34622229
http://dx.doi.org/10.1016/j.xcrm.2021.100392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484507/
https://www.ncbi.nlm.nih.gov/pubmed/34622229
http://dx.doi.org/10.1016/j.xcrm.2021.100392

Ejemplares similares